Amgen Wins Injunction On Sale Of Sanofi's Cholesterol Drug
Sanofi and Regeneron Pharmaceuticals must stop selling the cholesterol-lowering drug Praluent after a Delaware federal judge entered a permanent injunction in favor of Amgen Inc. on Thursday in a patent infringement suit...To view the full article, register now.
Already a subscriber? Click here to view full article